Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001062993-25-001087
Filing Date
2025-01-24
Accepted
2025-01-24 16:42:51
Documents
1
Period of Report
2025-01-22

Document Format Files

Seq Description Document Type Size
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.html 4  
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.xml 4 3711
  Complete submission text file 0001062993-25-001087.txt   5571
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Issuer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560
Business Address 510-293-8123
Quinlan Paul T (Reporting) CIK: 0001333277 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-22873 | Film No.: 25554705